153 related articles for article (PubMed ID: 26018686)
1. Variability of Hepatic 18F-FDG Uptake at Interim PET in Patients With Hodgkin Lymphoma.
Rubello D; Gordien P; Morliere C; Guyot M; Bordenave L; Colletti PM; Hindié E
Clin Nucl Med; 2015 Aug; 40(8):e405-10. PubMed ID: 26018686
[TBL] [Abstract][Full Text] [Related]
2. Factors affecting intrapatient liver and mediastinal blood pool ¹⁸F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin's lymphoma.
Chiaravalloti A; Danieli R; Abbatiello P; Di Pietro B; Travascio L; Cantonetti M; Guazzaroni M; Orlacchio A; Simonetti G; Schillaci O
Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1123-32. PubMed ID: 24562647
[TBL] [Abstract][Full Text] [Related]
3. In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma.
Hutchings M; Kostakoglu L; Zaucha JM; Malkowski B; Biggi A; Danielewicz I; Loft A; Specht L; Lamonica D; Czuczman MS; Nanni C; Zinzani PL; Diehl L; Stern R; Coleman M
J Clin Oncol; 2014 Sep; 32(25):2705-11. PubMed ID: 25071108
[TBL] [Abstract][Full Text] [Related]
4. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.
Rossi C; Kanoun S; Berriolo-Riedinger A; Dygai-Cochet I; Humbert O; Legouge C; Chrétien ML; Bastie JN; Brunotte F; Casasnovas RO
J Nucl Med; 2014 Apr; 55(4):569-73. PubMed ID: 24566003
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of Bone Marrow Tracer Uptake Pattern in Baseline PET Scans in Hodgkin Lymphoma: Results from an International Collaborative Study.
Zwarthoed C; El-Galaly TC; Canepari M; Ouvrier MJ; Viotti J; Ettaiche M; Viviani S; Rigacci L; Trentin L; Rusconi C; Luminari S; Cantonetti M; Bolis S; Borra A; Darcourt J; Salvi F; Subocz E; Tajer J; Kulikowski W; Malkowski B; Zaucha JM; Gallamini A
J Nucl Med; 2017 Aug; 58(8):1249-1254. PubMed ID: 28126883
[TBL] [Abstract][Full Text] [Related]
6. Whole-body diffusion-weighted MR and FDG-PET/CT in Hodgkin Lymphoma: Predictive role before treatment and early assessment after two courses of ABVD.
Albano D; Patti C; Matranga D; Lagalla R; Midiri M; Galia M
Eur J Radiol; 2018 Jun; 103():90-98. PubMed ID: 29803392
[TBL] [Abstract][Full Text] [Related]
7. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma.
Cerci JJ; Pracchia LF; Linardi CC; Pitella FA; Delbeke D; Izaki M; Trindade E; Soares J; Buccheri V; Meneghetti JC
J Nucl Med; 2010 Sep; 51(9):1337-43. PubMed ID: 20720036
[TBL] [Abstract][Full Text] [Related]
8. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.
Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K
AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746
[TBL] [Abstract][Full Text] [Related]
9. Liver standardized uptake value corrected for lean body mass at FDG PET/CT: effect of FDG uptake time.
Chirindel A; Alluri KC; Tahari AK; Chaudhry M; Wahl RL; Lodge MA; Subramaniam RM
Clin Nucl Med; 2015 Jan; 40(1):e17-22. PubMed ID: 24873794
[TBL] [Abstract][Full Text] [Related]
10. Semiquantitative Parameters in PSMA-Targeted PET Imaging with
Li X; Rowe SP; Leal JP; Gorin MA; Allaf ME; Ross AE; Pienta KJ; Lodge MA; Pomper MG
J Nucl Med; 2017 Jun; 58(6):942-946. PubMed ID: 27932557
[No Abstract] [Full Text] [Related]
11. Decisional early interim (18)F-fluoro-2-deoxy-D-glucose positron emission tomography after two cycles of chemotherapy in de novo Hodgkin lymphoma.
Iltis A; Eder V; Blasco H; Colombat P; Sénécal D
Acta Haematol; 2015; 133(2):172-8. PubMed ID: 25301496
[TBL] [Abstract][Full Text] [Related]
12. Baseline and ongoing PET-derived factors predict detrimental effect or potential utility of 18F-FDG PET/CT (FDG-PET/CT) performed for surveillance in asymptomatic lymphoma patients in first remission.
Morbelli S; Capitanio S; De Carli F; Bongioanni F; De Astis E; Miglino M; Verardi MT; Buschiazzo A; Fiz F; Marini C; Pomposelli E; Sambuceti G
Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):232-239. PubMed ID: 26283504
[TBL] [Abstract][Full Text] [Related]
13. Standardized uptake values for [¹⁸F] FDG in normal organ tissues: comparison of whole-body PET/CT and PET/MRI.
Heusch P; Buchbender C; Beiderwellen K; Nensa F; Hartung-Knemeyer V; Lauenstein TC; Bockisch A; Forsting M; Antoch G; Heusner TA
Eur J Radiol; 2013 May; 82(5):870-6. PubMed ID: 23394765
[TBL] [Abstract][Full Text] [Related]
14. Reproducibility of [18F]FDG PET/CT liver SUV as reference or normalisation factor.
Zwezerijnen GJC; Eertink JJ; Ferrández MC; Wiegers SE; Burggraaff CN; Lugtenburg PJ; Heymans MW; de Vet HCW; Zijlstra JM; Boellaard R
Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):486-493. PubMed ID: 36166080
[TBL] [Abstract][Full Text] [Related]
15. Two-time-point FDG PET/CT: liver SULmean repeatability.
Tahari AK; Paidpally V; Chirindel A; Wahl RL; Subramaniam RM
AJR Am J Roentgenol; 2015 Feb; 204(2):402-7. PubMed ID: 25615764
[TBL] [Abstract][Full Text] [Related]
16. Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients.
Ciammella P; Filippi AR; Simontacchi G; Buglione M; Botto B; Mangoni M; Iotti C; Merli F; Marcheselli L; Bisi G; Ricardi U; Versari A
Br J Radiol; 2016; 89(1061):20150983. PubMed ID: 27022777
[TBL] [Abstract][Full Text] [Related]
17. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.
Simontacchi G; Filippi AR; Ciammella P; Buglione M; Saieva C; Magrini SM; Livi L; Iotti C; Botto B; Vaggelli L; Re A; Merli F; Ricardi U
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1077-1083. PubMed ID: 26031367
[TBL] [Abstract][Full Text] [Related]
18. Variation of liver SUV on (18)FDG-PET/CT studies in women with breast cancer.
Groheux D; Delord M; Rubello D; Colletti PM; Nguyen ML; Hindié E
Clin Nucl Med; 2013 Jun; 38(6):422-5. PubMed ID: 23510894
[TBL] [Abstract][Full Text] [Related]
19. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
20. Liver SULmean at FDG PET/CT: interreader agreement and impact of placement of volume of interest.
Viner M; Mercier G; Hao F; Malladi A; Subramaniam RM
Radiology; 2013 May; 267(2):596-601. PubMed ID: 23297330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
